• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Aphena’s $21M Cookeville Expansion Nears Completion

    BioMed X Partners with Jansen Research & Development LLC

    Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial

    500+ Sites Join Inato’s Industry Marketplace

    Caprion-HistoGeneX Rebrands as CellCarta
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Aphena’s $21M Cookeville Expansion Nears Completion

    PromoCell Receives EXCiPACT Certification

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Aphena’s $21M Cookeville Expansion Nears Completion

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial

    Caprion-HistoGeneX Rebrands as CellCarta

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Lilly Completes $1B Acquisition of Prevail
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Baxter BioPharma Solutions

    PCI Pharma Services

    Syngene

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Aphena Pharma Solutions

    Emergent BioSolutions

    Reed-Lane

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    CMO/CDMO Sector Mega-Mergers & Acquisitions

    A look at recent M&A activity among contract service providers

    CMO/CDMO Sector Mega-Mergers & Acquisitions
    Related CONTENT
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    • LSNE Expands Fill Finish and Lyophilization Ops
    • Capricor, Lonza Enter CAP-1002 Development Agreement
    • Adagene Achieves CAR-T Collaboration Milestone
    Kristin Brooks, Contract Pharma10.02.17
    Similar to what the CRO industry experienced in the ten years from 2005-2015, consolidation has turned its sights on the CMO and CDMO sector. Leading global providers as well as smaller, specialty service providers are the target of acquisition efforts to gain/dominate market share. In line with increased outsourcing within the pharma/biopharma industry, demand for greater capacity, advanced technologies, and global infrastructure, for increasingly complex drug products, namely biologics, has prompted a flurry of M&A within the past nine months.
               
    Most recently, Catalent entered an agreement to acquire Cook Pharmica for $950 million, significantly expanding its position in biologics development and analytical services, manufacturing, and finished product supply.
               
    Cook Pharmica operates an 875,000 sq.-ft. development and manufacturing facility in Bloomington, IN with capabilities across biologics development, clinical and commercial cell culture manufacturing, formulation, finished-dose manufacturing, and packaging. For the twelve months ended June 30, 2017, the company generated $179 million in revenue.
               
    Additionally, 3SBio Inc., a Chinese biopharmaceutical company, through a joint venture formed with CPE Funds, acquired the CDMO business of Canada-based biologics manufacturer Therapure Biopharma for $290 million. With this acquisition, 3SBio enters the North American biopharmaceutical sector, and expands its CDMO business with manufacturing assets that enhance its technical biologics capabilities.
               
    Therapure Biopharma provides therapeutic protein development and manufacturing services, including technology transfer and process development, analytical development and testing, scale-up and cGMP manufacturing and aseptic fill/finish and lyophilization.

    In June, Albany Molecular Research was acquired by affiliates of The Carlyle Group and GTCR for $922 million. AMRI, a global contract research and manufacturing organization with locations in North America, Europe and Asia, has business segments including Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals (FC).
               
    In another major deal, Thermo Fisher Scientific, a leading maker of scientific instruments, acquired Patheon, a contract development and manufacturing organization for $7.2 billion, expanding its capabilities and efforts to become a one-stop shop for drug development and manufacturing services.
               
    Patheon has a network of facilities primarily in North America and Europe, and employs approximately 9,000 professionals worldwide. Earlier this year, Patheon acquired a 300,000 sq.-ft. API manufacturing facility in Florence, SC, from Roche Holdings, expanding the company’s capacity for manufacturing highly potent compounds and adding capabilities to support solid-state chemistry, micronization, and eventually, commercial spray drying. This was the company’s sixth acquisition in the last five years to expand pharma development and manufacturing services.
               
    The company generated 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher's Laboratory Products and Services Segment.
               
    In December 2016, Lonza acquired Capsugel for $5.5 billion in cash, expanding its market reach and contract development and manufacturing products businesses. The acquisition aims to integrate services in drug development, formulation, delivery technologies and manufacturing for the global pharma and consumer healthcare industries. The combined business will offer active pharmaceutical ingredients (APIs) and excipients to dosage forms and delivery technologies.
               
    Capsugel brings advanced oral dosage delivery technologies, including its hard capsule technologies, and the combined technologies and offerings will provide services in both large and small molecules. The company has approximately 3,600 employees and 13 facilities on three continents. The combined business would have had combined 2015 revenues of approximately CHF 4.8 billion.
     
    APIs, Early Development and Beyond
    In the early development arena, several CDMOs have expanded capabilities into later phases of the development and manufacturing process. For example, Evotec acquired Aptuit for $300 million, strengthening its outsourced drug discovery and development services. Aptuit offers services across drug discovery, preclinical testing and both drug substance and drug product manufacturing.
               
    Aptuit provides early discovery to mid-phase drug development services to the pharma and biopharma industry. It has approximately 750 employees working across three discovery, development and manufacturing facilities in Europe (Verona, Italy; Basel, Switzerland; and Oxford, UK).
               
    The acquisition substantially expands Evotec’s business and extends its offering through to investigational new drug (IND) submission and beyond to integrated drug substance and drug product and commercial manufacture.  
               
    In July, STA Pharmaceutical, a WuXi AppTec group company, merged with WuXi AppTec’s Pharmaceutical Development Services (PDS) division.
               
    The PDS division offers pre-formulation development, formulation development, as well as clinical trial material (CTM) manufacturing, packaging and labeling of oral solid dosage forms including tablets, capsules, sachets and oral solutions/suspensions. PDS also established various enabling technology platforms for low soluble drugs including spray dried dispersion, hot melt extrusion, micro or nano suspension and liquid-filled hard gelatin capsules. Two commercial-scale drug product manufacturing facilities currently under construction are expected to become operational later this year and early next year, respectively.
               
    STA Pharmaceutical, after this merger, will provide small molecule active pharmaceutical ingredient (API) and drug product services and enables STA to advance new chemical entities from preclinical stage to new drug application (NDA) and to market.
               
    Growth in the Cell Therapy arena has also prompted capability expansions. In June, Lonza acquired PharmaCell B.V., a cell and gene contract manufacturer in Europe with employees in Maastricht and Geleen (NL). In 2016 PharmaCell had sales of €11 million.
               
    PharmaCell was primarily selected due to its core expertise in autologous cell and gene therapy manufacturing, which includes experience with two commercial advanced therapy medicinal products (ATMPs)-licensed products. Autologous therapies use a patient’s own cells.
               
    Established in 2005 when cell manufacturing was still in its infancy, PharmaCell has since been the manufacturer of the only two European-approved commercial cell therapy products. PharmaCell has more than 6,000 square meters of GMP clean rooms, QC and other support spaces.

    In August, the FDA approved the first cell therapy, Novartis’ chimeric antigen receptor T cell (CAR-T) cell therapy, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL). It is the first FDA-approved CAR-T immunotherapy, which uses specifically developed Cell Therapy Systems (CTS) Dynabeads technology, part of Thermo Fisher's Cell Therapy Systems (CTS) portfolio. The magnetic beads isolate, activate and expand T cells that have been genetically engineered to recognize and fight cancer cells in each individual patient.
               
    In cell therapy manufacturing, CTS Dynabeads CD3/CD28 beads deliver a scalable platform that help to streamline production with high reproducibility. Dynabeads products are for research use only or for the manufacturing of cell-, gene- or tissue-based products.
               
    These highly sophisticated therapies will require equally advanced capabilities for service providers. We can expect to see more M&As drawing on the expertise of successful CMO/CDMOS.
    Related Searches
    • biologics development
    • cro industry
    • CRO
    • Technology Transfer
    Suggested For You
    Humanigen, Emergent Enter Covid-19 Partnership Humanigen, Emergent Enter Covid-19 Partnership
    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    LSNE Expands Fill Finish and Lyophilization Ops LSNE Expands Fill Finish and Lyophilization Ops
    Capricor, Lonza Enter CAP-1002 Development Agreement Capricor, Lonza Enter CAP-1002 Development Agreement
    Adagene Achieves CAR-T Collaboration Milestone  Adagene Achieves CAR-T Collaboration Milestone
    Drug Product Development, Manufacturing, and Packaging Drug Product Development, Manufacturing, and Packaging
    Irisys Receives NIH Contract for the Formulation of Drinabant Irisys Receives NIH Contract for the Formulation of Drinabant
    AGC Biologics Manufactures Orchard Therapeutics AGC Biologics Manufactures Orchard Therapeutics' Libmeldy
    Ajinomoto Bio-Pharma and Revance Therapeutics Partner Ajinomoto Bio-Pharma and Revance Therapeutics Partner
    Lonza Expands Conjugation Facility in Visp Lonza Expands Conjugation Facility in Visp
    Thermo Fisher Scientific Further Expands Global Footprint Thermo Fisher Scientific Further Expands Global Footprint
    Logistics4Pharma Facility Passes Inspection Logistics4Pharma Facility Passes Inspection
    Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact
    CDMO Stelis Continues Expansion CDMO Stelis Continues Expansion
    Recipharm Inks Covid-19 Vax Pact with Moderna Recipharm Inks Covid-19 Vax Pact with Moderna

    Related Online Exclusives

    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21

    • Clinical Trials | Drug Development | Information Technology
      Advancing Digital Endpoints in Clinical Trials

      Advancing Digital Endpoints in Clinical Trials

      An end-to-end approach to managing wearable devices through clinical development.
      Kristin Brooks, Contract Pharma 12.14.20

    • Drug Delivery | Drug Development
      Inhaled Drug Delivery Technology Trends

      Inhaled Drug Delivery Technology Trends

      The success of new inhaled medicines relies on the correct combination of formulation and device technology.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 11.24.20


    • Bioanalytical Services | cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      CDMOs: Keeping up with Science & Technology

      CDMOs: Keeping up with Science & Technology

      Enhancing the development of increasingly advanced and complex drug candidates is needed to drive growth in the industry.
      Kristin Brooks, Contract Pharma 11.12.20

    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Contract Pharma 08.25.20


    • Drug Development | Information Technology
      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Theft of IP belonging to companies developing biologics and other drugs, including COVID-19 treatments and vaccines, poses a threat to innovation.
      Kristin Brooks, Contract Pharma 08.19.20

    • Drug Development | Industry News
      Top Companies Report: Biogen

      Top Companies Report: Biogen

      Expands pipeline of disease-modifying therapies for Alzheimer’s and Parkinson’s, adds gene therapies focused on AAV treatments, bolsters biosimilars portfolio.
      Kristin Brooks, Contract Pharma 07.10.20

    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20


    • Drug Development | Information Technology
      Advancing AI Initiatives in R&D

      Advancing AI Initiatives in R&D

      Richard Lee of ACD/Labs discusses the possibilities of using AI in R&D, and what this outlook means for IT leaders at pharmaceutical organizations.
      Kristin Brooks, Contract Pharma 06.11.20

    • Clinical Trials | CRO News | Drug Development | Information Technology | R&D
      CRO Industry Update

      CRO Industry Update

      Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
      Kristin Brooks, Contract Pharma 04.27.20

    • Drug Development | R&D
      COVID-19 and the Importance of Combating Antimicrobial Resistance

      COVID-19 and the Importance of Combating Antimicrobial Resistance

      Dr. Frank of Working to Fight AMR discusses the global COVID-19 pandemic and the critical need to address the public health crisis of Antimicrobial Resistance
      Kristin Brooks, Contract Pharma 04.13.20


    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trials | Drug Development | Scale-up/Technology Transfer
      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Contract Pharma 04.03.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      COVID-19 Vaccine Response

      COVID-19 Vaccine Response

      ICON execs discuss developments in vaccine research efforts and key challenges of delivering a coronavirus vaccine
      Kristin Brooks, Contract Pharma 04.01.20

    • cGMP Manufacture | Drug Development | Logistics | Supply Chain
      COVID-19: Business Update

      COVID-19: Business Update

      Thermo Fisher Scientific provides perspective on the COVID-19 pandemic and how the company is working to help minimize disruptions
      Kristin Brooks, Contract Pharma 03.30.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • CDMO Northway Biotech Expands In U.S.
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Stevanato Group Launches After-sales Service Offering
    • X-Chem Acquires IntelliSyn and AviSyn
    • Aphena’s $21M Cookeville Expansion Nears Completion
    • BioMed X, Janssen Enter Oral Drug Delivery Alliance
    • Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kerry Launches Web-Based Tool for Plant-Based Formulation Challenges
    Wiley’s Finest Earns Accolades for Taste of Omega-3 Products
    Clinical Evidence Suggests Potential Oral Benefits for Curcumin Extract
    Coatings World

    Latest Breaking News From Coatings World

    Scott McLaughlin to Race in PPG Colors During Rookie INDYCAR Season
    Vink Chemicals Offers parmetol PSG
    Palmer Holland Expands Roles, Positions Of Business Teams
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Butterfly Network Appoints New Leader
    BD Names Chairman of Board
    Interplex Acquires OCP Group
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Stevanato Group Launches After-sales Service Offering
    X-Chem Acquires IntelliSyn and AviSyn
    Aphena’s $21M Cookeville Expansion Nears Completion
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Estée Lauder Companies Announces Game-Changing Sustainability Goals for Travel Retail
    Aura Introduces Customizable Hair Care
    Corpack Creates Custom Packaging for Marlies Möller Hair Care Line
    Happi

    Latest Breaking News From Happi

    Harry’s Launches ‘Headquarters’
    Henkel Recognizes Top Suppliers
    Estée Lauder Travel Retail's Sustainability Goals
    Ink World

    Latest Breaking News From Ink World

    Smurfit Kappa Sets New Sustainability Targets with Better Planet 2050
    Paragon Expands Direct Mail Capabilities with Ricoh Pro VC70000
    Rondo Ganahl Adds Koenig & Bauer Durst Delta SPC 130
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Great Lakes Label debuts new website
    Epson partner creates label applicators for pharmaceutical products
    ACTEGA removes chemicals from laminating adhesives
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Kimberly-Clark Releases Q4, Full Year Results
    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Spinal Elements' Lucent XP-Curved Expandable TLIF Gains FDA Nod
    FDA OKs OrthoSpin's 2nd Gen Robotic, Digital External Fixation System
    Nextremity Solutions Enters Supply Agreement with Fort Wayne Metals
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    North American Semiconductor Equipment Industry Posts December 2020 Billings
    First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward
    PRINTING United Alliance Announces TAGA Presents Virtual Event

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login